Eupraxia Pharmaceuticals Announces Positive 1-Year Clinical Results from RESOLVE Trial for Eosinophilic Esophagitis with EP-104GI
I'm PortAI, I can summarize articles.
Eupraxia Pharmaceuticals Inc. announced positive results from its Phase 1b/2a RESOLVE trial for EP-104GI, a treatment for eosinophilic esophagitis (EoE). Two-thirds of patients in Cohort 5 maintained clinical remission at 12 months post-treatment. All cohorts showed significant improvements in tissue health, with no serious adverse events reported. Plasma levels of fluticasone remained stable, suggesting EP-104GI could enhance current EoE treatments with a potential once-a-year therapy. Further 12-month data from a larger patient group is expected later this year.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments